Apremilast CAS 608141-41-9 Raw Powder

CAS: 608141-41-9 

MF: C22H24N2O7S

Specification​: 99% min Apremilast Powder

Sample:  Apremilast Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Apremilast Powder Usage and Synthesis:

Apremilast Powder is an oral medication used to treat psoriasis and psoriatic arthritis. It works by inhibiting an enzyme called phosphodiesterase 4 (PDE4), which is involved in the inflammation process. By reducing inflammation, apremilast can improve symptoms such as redness, itching, and joint pain. Apremilast CAS 608141-41-9 is typically taken twice daily and may take several weeks to show its full effect. It is important to follow the dosage instructions provided by your healthcare provider and to report any side effects or concerns. Common side effects of apremilast include diarrhea, nausea, headache, and upper respiratory tract infection.

Pharmacokinetics of Apremilast Powder:

Apremilast is used in the treatment of adults with active psoriatic arthritis (PsA). Apremilast tablets are a drug that is primarily used for psoriasis. The FDA approved Otezla (apremilast) for the treatment of adult patients with active psoriatic arthritis (PsA). Most people present with psoriasis first and are later diagnosed with PsA. joint pain, stiffness and swelling are the main signs and symptoms of PsA. Drugs currently approved for use in PsA include glucocorticoids, tumor necrosis factor (TNF) blockers and interleukin-12/interleukin-23 inhibitors.

Applications of Apremilast Powder:

Psoriasis, commonly known as psoriasis, is a chronic inflammatory skin disease with a long course and a tendency to recur, in some cases almost for life. The disease is predominantly affecting young adults and has a significant impact on the physical and mental health of patients. The clinical manifestations are mainly erythematous and scaly, and can develop all over the body, with scalp and extremities more common, mostly aggravated in winter.
Apoest is a new oral, small molecule phosphodiesterase 4 (PDE4) inhibitor. Apst inhibits PDE4 activity, increases intracellular cyclic adenosine phosphate levels, further regulates the expression of tumor necrosis factor and other inflammatory cytokines, and ultimately suppresses the inflammatory response.

What are the advantages of Apest?

Compared to biologics such as Sulginomab, Xumel, Enzyme or other traditional therapeutic drugs for psoriasis and psoriatic arthritis, the distinct advantages of Apst are.

(1) Good selectivity and wide applicability

As a selective inhibitor of phosphodiesterase-4 (PDE-4), it is effective in both psoriasis and arthritic psoriasis, including in patient groups previously treated with biologics or conventional systemic drugs.

(2) Oral administration, easy to take

As a small molecule compound, oral administration is convenient and portable for patients, avoiding skin irritation and other adverse reactions caused by injections and eliminating the need for frequent monitoring of laboratory indicators.

(3) Single administration, precise therapeutic effect

It can be administered as a single agent and its efficacy is no worse than that of biological agents such as sulforaphane, adalimumab (Xumel), etanercept (Enzyme) and infliximab, and is significantly better than other traditional therapeutic drugs.

(4) Low recurrence rate and good safety

Clinical data showed that the significant improvement in the severity of nail, scalp and palmoplantar (hand and foot) psoriasis achieved at 16 weeks of treatment was maintained throughout the 52 weeks, resulting in clinically significant and lasting improvement in the patient's condition.

(5) Short half-life and high tolerability

Apstat has a short half-life and a high safety margin if treatment needs to be interrupted. Therefore, Apstat can be used in patients with plaque psoriasis and arthritic psoriasis for whom conventional systemic drug therapy is ineffective or contraindicated, as well as in patients with poor efficacy or poor compliance with biologics.